There was a medical scare at the Oval Office on Thursday as a man suddenly collapsed behind President Trump, sending reporters out of the room as Dr. Oz rushed to help the individual, the Daily Mail reported.

The incident happened in the middle of a livestreamed press conference where Trump, pharma executives and top health officials touted new agreements with drugmakers to lower the cost of obesity drugs, or "the fat drug" as Trump calls it. Attendees included executives from Novo Nordisk and Eli Lilly, which make Ozempic and Zepbound, respectively.

Oval Office fainting incident

During comments from Eli Lilly CEO David Ricks, a man started to collapse, causing Trump's director of Centers for Medicare and Medicaid Services, Dr. Oz, to spring into action to ease the man to the ground.

🚨BREAKING: A pharmaceutical representative collapses during President Trump’s Oval Office announcement, as reporters are swiftly escorted out of the room. pic.twitter.com/RskICBEcJC

— Fox News (@FoxNews) November 6, 2025

After about 30 minutes, reporters were let back inside. Trump said the man is doing "fine."

"One of the representatives of one of the companies, got a little bit light-headed. You saw he went down. And he's fine. They just sent him out, he's got doctor's care, but he's fine," Trump said. "So we had a little bit of an interruption, sorry about that," Trump said.

Man is doing fine

Later, Ricks said the man was a guest of Eli Lilly's and he is doing well.

"If you've ever been in the Oval Office, you stand a long time and it's warm. I'm pleased to say that the White House medical staff did a great job, and he's doing great, so nothing to be concerned about. Thanks for your concern,” Ricks said.

The man was incorrectly identified at first as Gordon Findlay, the global brand director for Novo Nordisk.

The company told Fox5 that two Novo Nordisk executives were present, and Findlay was not one of them.

Trump lower costs

Under Trump's new deal, the cost of weight loss drugs like Novo Nordisk's Wegovy could drop from over $1,000 per month to as little as $150 per month for the lowest doses.

According to the White House, eligible Medicare patients will soon be able to access weight loss drugs with a $50 co-pay. Americans will also be able to purchase the drugs directly from the manufacturers for $350 a month through the upcoming TrumpRX website. If the FDA approves it, the pill version of Wegovy will be available for $150 a month for the initial dose.

Obesity is a health epidemic in America, affecting nearly half of adults. Secretary of Health Robert F. Kennedy Jr., who has prioritized the issue, said Trump's deal could help Americans lose "125 million pounds by this time next year."

"'It is going to have dramatic effects on human health in his country," the HHS secretary added.